IL192357A0 - Pharmaceutical compositions containing a farnesyl transferase inhibitor - Google Patents

Pharmaceutical compositions containing a farnesyl transferase inhibitor

Info

Publication number
IL192357A0
IL192357A0 IL192357A IL19235708A IL192357A0 IL 192357 A0 IL192357 A0 IL 192357A0 IL 192357 A IL192357 A IL 192357A IL 19235708 A IL19235708 A IL 19235708A IL 192357 A0 IL192357 A0 IL 192357A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
compositions containing
transferase inhibitor
farnesyl transferase
farnesyl
Prior art date
Application number
IL192357A
Other languages
English (en)
Original Assignee
Link Medicine Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Link Medicine Corp filed Critical Link Medicine Corp
Publication of IL192357A0 publication Critical patent/IL192357A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL192357A 2005-12-23 2008-06-22 Pharmaceutical compositions containing a farnesyl transferase inhibitor IL192357A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75380905P 2005-12-23 2005-12-23
PCT/US2006/048852 WO2007075923A2 (en) 2005-12-23 2006-12-22 Treatment of synucleinopathies

Publications (1)

Publication Number Publication Date
IL192357A0 true IL192357A0 (en) 2009-08-03

Family

ID=38218630

Family Applications (1)

Application Number Title Priority Date Filing Date
IL192357A IL192357A0 (en) 2005-12-23 2008-06-22 Pharmaceutical compositions containing a farnesyl transferase inhibitor

Country Status (7)

Country Link
US (1) US20070213366A1 (enExample)
EP (2) EP2545919A1 (enExample)
JP (1) JP2009521470A (enExample)
AU (1) AU2006331542A1 (enExample)
CA (1) CA2634598A1 (enExample)
IL (1) IL192357A0 (enExample)
WO (1) WO2007075923A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155197A4 (en) * 2007-03-09 2011-10-12 Link Medicine Corp TREATMENT OF LYSOSOMAL STORAGE DISEASES
WO2008137692A1 (en) * 2007-05-03 2008-11-13 Link Medicine Corporation Treatment of synucleinopathies
WO2009151683A2 (en) 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
WO2010057006A1 (en) 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100160372A1 (en) * 2008-11-13 2010-06-24 Link Medicine Corporation Treatment of proteinopathies using a farnesyl transferase inhibitor
EP3521451A1 (en) 2010-11-17 2019-08-07 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
US20140349308A1 (en) * 2011-09-19 2014-11-27 C2N Diagnostics Methods for the Diagnosis and Treatment of Neurological and Neurodegenerative Diseases, Disorders and Associated Processes
WO2019025424A1 (en) * 2017-08-04 2019-02-07 Universitat Autonoma De Barcelona COMPOUNDS FOR TREATING SYNUCLEINOPATHIES
AU2019208011B2 (en) 2018-01-12 2025-06-05 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
WO2019140231A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
EP4028014A1 (en) * 2019-09-12 2022-07-20 Stellate Therapeutics Compounds for treating neurodegenerative diseases

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US650377A (en) 1899-01-03 1900-05-29 John F Dornfeld Malting-drum.
HU169186B (enExample) * 1974-06-13 1976-10-28
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US4933324A (en) 1988-02-26 1990-06-12 Shashoua Victor E Fatty acid-neuroactive drug conjugate as a prodrug
US6107499A (en) 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4939174A (en) 1988-02-26 1990-07-03 Shashoua Victor E Appetite suppression with dopamine-fatty acid conjugates
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
IL123568A (en) 1995-12-08 2001-08-08 Janssen Pharmaceutica Nv History (Imidazole - 5Il) Methyl-2-quinolinone inhibitors of Prenzyl transferase, their preparation, pharmaceutical preparations containing them and their preparation and drugs containing them
JPH10215175A (ja) 1996-11-29 1998-08-11 Sony Corp Ｐｌｌ回路及び信号再生装置
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
KR100520401B1 (ko) 1997-04-25 2005-10-12 얀센 파마슈티카 엔.브이. 파네실 트랜스퍼라제 억제작용을 갖는 퀴나졸리논
CN1231215C (zh) 1997-06-02 2005-12-14 詹森药业有限公司 (咪唑－5－基)甲基－2－喹啉酮衍生物用作平滑肌细胞增殖抑制剂
TW527355B (en) * 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
ATE238811T1 (de) 1998-07-06 2003-05-15 Janssen Pharmaceutica Nv Inhibitoren von farnesylprotein-transferase mit radiosensibilisierenden eigenschaften
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
GEP20033001B (en) 1998-08-27 2003-06-25 Pfizer Prod Inc Alkynyl-Substituted Quinolin-2-One Derivatives Useful As Anticancer Agents
JP4725940B2 (ja) 1998-12-23 2011-07-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ １，２−環付加キノリン誘導体
JP4090200B2 (ja) * 1999-02-11 2008-05-28 ファイザー・プロダクツ・インク 抗癌薬として有用なヘテロアリール置換キノリン−２−オン誘導体
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
JP5491681B2 (ja) 2000-02-04 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
EP1267848B1 (en) 2000-02-24 2007-10-17 Janssen Pharmaceutica N.V. Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer
WO2001064199A2 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
WO2001064197A2 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
CA2397694A1 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Farnesyl protein transferase inhibitor combinations
EP1267871A2 (en) 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
EP1261348A2 (en) 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
EP1267929A2 (en) 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with an her2 antibody
US20030100553A1 (en) 2000-02-29 2003-05-29 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with camptothecin compounds
WO2001064252A2 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
US20030186925A1 (en) 2000-02-29 2003-10-02 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
WO2001064226A2 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
WO2001064196A2 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
EP1322636A1 (en) 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6- (substituted phenyl)methyl]-quinoline and quinazoline derivatives
US7196094B2 (en) 2000-09-25 2007-03-27 Janssen Pharmaceutica, N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
ES2261523T3 (es) 2000-11-28 2006-11-16 Janssen Pharmaceutica N.V. Inhibidores de farnesil proteina transferasa para el tratamiento de enfermedad intestinal inflamatoria.
CA2632091C (en) 2000-12-19 2011-03-22 Pfizer Products Inc. Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
JP4969016B2 (ja) 2001-02-15 2012-07-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物
HU230282B1 (hu) 2001-03-12 2015-12-28 Janssen Pharmaceutica N.V Eljárás imidazol-származékok előállítására
JP2004526776A (ja) 2001-04-25 2004-09-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 悪液質を治療するためのファルネシルタンパク質トランスフェラーゼ阻害剤
ITMI20011728A1 (it) * 2001-08-06 2003-02-06 Consorzio Per Le Ricerche E Lo Vettore per l'integrazione sito-specifica di sequenze di dna eterologhe in lieviti metilotrofi
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
US20040260076A1 (en) * 2002-10-11 2004-12-23 Castillo Gerardo M. Isolation, purification and synthesis of procyanidin B2 and uses thereof
WO2003080058A1 (en) 2002-03-22 2003-10-02 Janssen Pharmaceutica. N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
US20030050323A1 (en) 2002-08-28 2003-03-13 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
US20030125268A1 (en) 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
US20030060480A1 (en) 2002-08-28 2003-03-27 Horak Ivan David Farnesyl protein transferase inhibitor combinations with vinca alkaloids
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
JP2007538004A (ja) * 2004-03-18 2007-12-27 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy

Also Published As

Publication number Publication date
US20070213366A1 (en) 2007-09-13
CA2634598A1 (en) 2007-07-05
WO2007075923A3 (en) 2007-11-15
EP2545919A1 (en) 2013-01-16
AU2006331542A1 (en) 2007-07-05
WO2007075923A2 (en) 2007-07-05
EP1968591A4 (en) 2010-02-17
JP2009521470A (ja) 2009-06-04
EP1968591A2 (en) 2008-09-17

Similar Documents

Publication Publication Date Title
IL192357A0 (en) Pharmaceutical compositions containing a farnesyl transferase inhibitor
IL193243A0 (en) Pharmaceutical compositions containing a thiazolidinedione derivative
IL198869A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A PDGFRa ANTAGONIST
ZA200810023B (en) Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
ZA200808361B (en) DPP IV inhibitor formulations
IL189036A0 (en) Pharmaceutical composition comprising a dpp-iv inhibitor
IL193894A0 (en) Pharmaceutical compositions containing luliconazole for external use
EP2001498A4 (en) PHARMACEUTICAL COMPOSITIONS
IL194176A0 (en) Pharmaceutical compositions
GB0713625D0 (en) Pharmaceutical compositions
PL2079727T3 (pl) Inhibitory kinazy
PT2094708E (pt) Pirrolopirazina como inibidor da cinase syk
SI2124556T1 (sl) Farmacevtske sestave
IL182703A0 (en) Pharmaceutical compositions comprising a camtothecin derivative
IL187748A0 (en) Pharmaceutical compositions containing misoprostal
ZA200707070B (en) Analgesic compositions
SI1928409T1 (sl) Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid
PL1885339T3 (pl) Formulacje inhibitora src/abl
IL193774A0 (en) Pharmaceutical compositions containing a 3,5-seco-4-norcholestane derivative
IL198698A0 (en) Pharmaceutical compositions comprising a bisphosphonate compound
IL191680A0 (en) Pharmaceutical compositions containing revaprazen or a salt thereof
IL184631A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A Wht3a PROTEIN
IL192188A0 (en) Pharmaceutical compositions containing triaryl methane compounds
IL192677A0 (en) Pharmaceutical compositions containing a hydroxylamine or ester derivative thereof
SG10201601998PA (en) Compositions containing lignan-class compounds